Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin and Glofitamab in Relapsed/Refractory DLBCL
NCT07702851Phase 2Not yet recruiting
- Sponsor
- Yonsei University
- Start
- Sep 2026
- Primary completion
- Aug 2030
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin and glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Yonsei University. Primary endpoint: Complete response rate at 36 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotinglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07702851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07702851.